|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Compared with wild-type BRAF, the BRAF(V600E) mutation was associated with aggressive clinicopathological factors, including extrathyroidal extension, higher TNM stage, lymph node metastasis, and recurrence, and was associated with reduced overall survival; however, there was no significant association between the presence of BRAF mutation and distant metastasis.
|
27600854 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Further, no significant correlation of V600E expression with clinicopathologic parameters of aggressiveness such as lymph node metastasis, peritumoral infiltration, or perithyroidal infiltration was found.
|
22592144 |
2012 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
In 26 studies, compared with the patients who had the wild-type BRAF genes, the PTC patients with the BRAF(V600E) mutation had increased ORs of an extrathyroidal invasion (OR, 2.14; 95% CI, 1.68-2.73), a lymph node metastasis (OR, 1.54; 95% CI, 1.21-1.97), and an advanced TNM stage (OR, 2.00; 95% CI, 1.61-2.49).
|
21882184 |
2012 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Additionally, there were significant associations (P<0.05) between BRAF(V600E) and a higher tumor-node-metastasis staging (III/IV), and between miR-21* over-expression and lymph node metastasis.
|
23416953 |
2013 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutation-positive cancers (55.3%) were more frequently associated with lymph node metastasis (p=0.01) and advanced TNM stage (III-IV) (p=0.03).
|
24787545 |
2014 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF c.1799T>A (p.Val600Glu) substitution was present in 59.0% Chinese PTCs, more frequently observed in patients with lymph node metastasis (P = 1.6 × 10(-4)).
|
26941397 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
One case not meeting criteria for NIFTP maintained the diagnosis of encapsulated FVPTC without invasion but demonstrated significant mitotic activity (three mitoses/ten HPF) and lacked lymph node metastases and BRAF V600E mutation.
|
29368294 |
2018 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
No significant differences were observed in either the occurrence or the allele percentage of V600E mutation between the 2 groups of PTCs with or without LNMs.
|
23533235 |
2013 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
In a series of 33 cases, 21 harbored the T1799A mutation in the primary tumors, and 17 (81%) of them harbored the same mutation also in the paired lymph node metastases.
|
15998781 |
2005 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation, BRAF V600E IHC, low ΔCt, and high BRAF RNA ISH were significantly associated with lymph node metastasis.
|
25468810 |
2015 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation status was not associated with clinicopathologic characteristics of aggressive behavior such as extrathyroidal extension, lymph node metastases, higher T-categories, male sex, and greater age.
|
25482468 |
2015 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) in PTC predicts an increased risk of lymph node metastasis, extra-thyroidal extension and reduced disease-free survival.
|
27138882 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, PTCs exhibiting BRAF V600E mutation (p = 0.01), ETE (p < 0.01), and lymph node metastasis (p = 0.02) were associated with higher ICAM-1 levels.
|
21879273 |
2012 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E was associated with aggressive tumor factors, including lymph node metastasis (P=0.001) and advanced disease stage (P=0.009).
|
31602213 |
2019 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
We present a case of a woman with BRAF V600E-mutated malignant melanoma and rapidly progressing liver, bone, and lymph node metastases.
|
29215399 |
2018 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
On the contrary, no link could be detected between expression of BRAF(V599E) and age at diagnosis, gender, dimension, and local invasiveness of the primary cancer, presence of lymph node metastases, tumor stage, and multifocality of the disease.
|
15126572 |
2004 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
In thyroid cancer, the V600E mutation occurs with greater frequently in aggressive subtypes of PTC, and in individuals that present at advanced stages of disease with extra-thyroidal extension and/or lymph node metastases.
|
19356676 |
2009 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation was significantly associated with age (≥ 45 years), tumor size (>1 cm), extrathyroidal extension, and cervical lymph node metastases (P < 0.05).
|
22190222 |
2012 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Of 63 patients with BRAF V600E-mutated mCRC and sufficient clinical data, 27 (42.9%) had right-sided colon tumors, 19 (30.2%) had left-sided colon tumors, and 17 (26.9%) had rectal tumors; 26 (41.3%) had peritoneal metastases, and 50 (79.4%) had distant lymph node metastases.
|
29037218 |
2017 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
By contrast, positive status of BRAF(V600E) mutation was a significant predictor of multifocality (OR = 1.23; 95%CI = 1.14-1.32), extrathyroidal extension (OR = 2.23; 95%CI = 1.90-2.63), TNM stage (OR = 1.67; 95%CI = 1.53-1.81), lymph node metastasis (OR = 1.67; 95%CI = 1.45-1.93), vascular invasion (OR = 1.47; 95%CI = 1.22-1.79) and recurrence/persistence (OR = 2.33; 95%CI = 1.71-3.18).
|
26871894 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
There was no significant correlation with BRAF (V600E) mutation and age, gender, tumor size, ETE, central lymph node metastasis, the status of pT, pN1a-b, and distant metastasis.
|
26951110 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
We report a 65-year-old woman with anaplastic thyroid carcinoma (BRAF V600E mutation) who had lymph node metastases (pT4 N1b) treated by total thyroidectomy, postoperative radiotherapy, adjuvant chemotherapy (paclitaxel and pazopanib) and targeted therapy (vemurafenib).
|
26347145 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
In patients with conventional papillary thyroid cancer, BRAF V600E mutation was associated with older age (P = 0.0381), lymph node metastasis (P = 0.0323), distant metastasis (P = 0.045), higher TNM stage (I and II vs. III and IV, P = 0.0389), and recurrent and persistent disease (P = 0.009) with a median follow-up time of 6.0 years.
|
17717450 |
2007 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Expression of BRAF V600E, RET/PTC, and concomitant expression of BRAF V600E and RET/PTC were significantly associated with patient age and lymph node metastasis (P<0.05).
|
30254191 |
2018 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
The results showed that the BRAF (V600E) mutation was associated with extra-thyroidal extension (OR = 2.09, 95 % CI = 1.69-2.58), advanced TNM stage (OR = 1.90, 95 % CI = 1.62-2.22), lymph node metastasis (OR = 1.68, 95 % CI = 1.41-2.01), multifocality (OR = 1.22, 95 % CI = 1.06-1.40), and recurrence (OR = 2.50, 95 % CI = 1.73-3.59).
|
24389984 |
2014 |